<DOC>
	<DOCNO>NCT00087282</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , irinotecan flavopiridol , work different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : This phase II trial study well give irinotecan together flavopiridol work treat patient advanced liver cancer .</brief_summary>
	<brief_title>Irinotecan Flavopiridol Treating Patients With Advanced Liver Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine time progression patient advance hepatocellular carcinoma treat irinotecan flavopiridol . Secondary - Determine response rate overall survival patient treat regimen . - Determine toxicity regimen patient . OUTLINE : This open-label , non-randomized study . Patients receive irinotecan IV 30 minute flavopiridol IV 1 hour day 1 , 8 , 15 , 22 . Courses repeat every 42 day absence disease progression unacceptable toxicity . PROJECTED ACCRUAL : A total 16-32 patient accrue study within 2 year .</detailed_description>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Alvocidib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm hepatocellular carcinoma Advanced disease Measurable disease At least 1 unidimensionally measurable lesion ≥ 20 mm conventional technique OR ≥ 10 mm spiral CT scan Prior local therapy ( e.g. , surgery , hepatic arterial embolization , radiofrequency ablation , cryoablation ) allow provide therapy complete ≥ 8 week study entry AND ≥ 1 follow condition meet : Target lesion subject local therapy 25 % increase size target lesion within field prior local therapy Lesions treat external beam radiotherapy acceptable target lesion ChildPugh class A B status liver cirrhosis present Score 7 8 No know brain metastasis PATIENT CHARACTERISTICS : Age 18 Performance status Karnofsky 70100 % Life expectancy Not specify Hematopoietic Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 75,000/mm^3 WBC ≥ 3,000/mm^3 Hepatic See Disease Characteristics AST ALT ≤ 2.5 time upper limit normal Bilirubin ≤ 1.5 mg/dL Renal Creatinine normal OR Creatinine clearance ≥ 60 mL/min Cardiovascular No symptomatic congestive heart failure No unstable angina pectoris No deep vein thrombosis within past 6 month Patients maintain anticoagulation therapy event occur 6 month ago eligible No myocardial infarction within past 6 month No cardiac arrhythmia within past 6 month Ratecontrolled atrial fibrillation allow stable least 6 month Pulmonary No pulmonary embolus within past 6 month Patients maintain anticoagulation therapy event occur 6 month ago eligible Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 3 month study participation No prior allergic reaction attribute compound similar chemical biological composition flavopiridol irinotecan No clinically significant gastrointestinal bleeding require hospitalization within past month No active ongoing infection No psychiatric illness social situation would preclude study compliance No uncontrolled illness No malignancy within past 3 year except carcinoma situ cervix , adequately treat basal cell skin cancer , superficial bladder tumor [ Ta , Tis , T1 ] PRIOR CONCURRENT THERAPY : Biologic therapy No prior systemic biologic therapy Chemotherapy No prior systemic chemotherapy hepatocellular carcinoma No concurrent chemotherapy Endocrine therapy Not specify Radiotherapy See Disease Characteristics Surgery See Disease Characteristics No prior organ allograft Other No concurrent combination antiretroviral therapy HIVpositive patient No concurrent vitamin , antioxidant , herbal preparation supplement Singletablet multivitamin allow No concurrent investigational agent No concurrent anticancer agent therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2005</verification_date>
	<keyword>adult primary hepatocellular carcinoma</keyword>
	<keyword>advanced adult primary liver cancer</keyword>
	<keyword>recurrent adult primary liver cancer</keyword>
</DOC>